AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 34424563 — intervention group
Group type: COMPARATOR
Intervention: Weed removal at the two true-leaf stage
Number of subjects: 4
Study 34424563 — intervention group
Group type: EXPERIMENTAL
Intervention: Weed addition at the two true-leaf stage until harvest
Number of subjects: 4
Study 32739611 — intervention group
Group type: EXPERIMENTAL
Intervention: Kabochan engagement group
Number of subjects: 103
Study 32739611 — intervention group
Group type: COMPARATOR
Intervention: Usual care group
Number of subjects: 103
Study 35101993 — intervention group
Group type: EXPERIMENTAL
Intervention: nHFOV
Number of subjects: 30
Study 35101993 — intervention group
Group type: COMPARATOR
Intervention: nCPAP
Number of subjects: 30
Study 34479732 — intervention group
Group type: EXPERIMENTAL
Intervention: Contrast agent applied to the posterior ulnar recurrent artery
Number of subjects: 20
Study 34479732 — intervention group
Group type: EXPERIMENTAL
Intervention: Contrast agent applied to the inferior ulnar collateral artery
Number of subjects: 20
Study 34479732 — intervention group
Group type: EXPERIMENTAL
Intervention: Contrast agent applied to the superior ulnar collateral artery
Number of subjects: 20
Study 34479732 — intervention group
Group type: EXPERIMENTAL
Intervention: Physiologic blood flow simulation
Number of subjects: 20
Study 35863991 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab (BEV) during second-line chemotherapy
Number of subjects: 138
Study 35863991 — intervention group
Group type: EXPERIMENTAL
Intervention: Secondary cytoreductive surgery (CRS)
Number of subjects: 138
Study 35863991 — intervention group
Group type: COMPARATOR
Intervention: Non-Bevacizumab (non-BEV) during second-line chemotherapy
Number of subjects: 138
Study 35863991 — intervention group
Group type: COMPARATOR
Intervention: No surgery
Number of subjects: 138
Study 33472921 — intervention group
Group type: EXPERIMENTAL
Intervention: IV tPA treatment
Number of subjects: 255
Study 33472921 — intervention group
Group type: COMPARATOR
Intervention: No acute intervention (control)
Number of subjects: 255
Study 33377265 — intervention group
Group type: EXPERIMENTAL
Intervention: Vinegar drink containing 25 mmol acetate
Number of subjects: 10
Study 33377265 — intervention group
Group type: COMPARATOR
Intervention: Control drink
Number of subjects: 10
Study 35970278 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 gram of IV TXA preoperatively
Number of subjects: 100
Study 35970278 — intervention group
Group type: COMPARATOR
Intervention: No TXA (control group)
Number of subjects: 100
Study 33741504 — intervention group
Group type: EXPERIMENTAL
Intervention: MPLA
Number of subjects: 30
Study 33741504 — intervention group
Group type: COMPARATOR
Intervention: LPS
Number of subjects: 30
Study 35556322 — intervention group
Group type: EXPERIMENTAL
Intervention: Beetroot juice (BRJ; 140 ml containing 800 mg nitrate per day)
Number of subjects: 14
Study 35556322 — intervention group
Group type: COMPARATOR
Intervention: Placebo (140 ml nitrate-depleted BRJ, daily)
Number of subjects: 14
Study 32093630 — intervention group
Group type: COMPARATOR
Intervention: Treatment 1 (T1) - messages with information on their own adherence levels
Number of subjects: 0
Study 32093630 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment 2 (T2) - messages with information on their own adherence and peer adherence levels
Number of subjects: 0
Study 32093630 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 36112539 — intervention group
Group type: EXPERIMENTAL
Intervention: Liquified petroleum gas (LPG) stove and fuel intervention
Number of subjects: 3195
Study 34241574 — intervention group
Group type: EXPERIMENTAL
Intervention: Physician-assisted death (PAD) for psychiatric suffering
Number of subjects: 500
Study 34241574 — intervention group
Group type: EXPERIMENTAL
Intervention: Physician-assisted death (PAD) for somatic disease
Number of subjects: 500
Study 34241574 — intervention group
Group type: EXPERIMENTAL
Intervention: Reasons for supporting psychiatric PAD
Number of subjects: 500
Study 34241574 — intervention group
Group type: EXPERIMENTAL
Intervention: Reasons for not supporting psychiatric PAD
Number of subjects: 500
Study 32902831 — intervention group
Group type: EXPERIMENTAL
Intervention: Guideline release (2019 Canadian Guideline for Physical Activity throughout Pregnancy)
Number of subjects: 1995
Study 32902831 — intervention group
Group type: EXPERIMENTAL
Intervention: General Population, Academics, Exercise Specialists, Medical Professionals tweeting about prenatal PA
Number of subjects: 1995
Study 32902831 — intervention group
Group type: EXPERIMENTAL
Intervention: Geographical distribution of Tweets
Number of subjects: 1995
Study 35709207 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimedia pain management education (PME) through seven educational CDs at home
Number of subjects: 90
Study 35709207 — intervention group
Group type: EXPERIMENTAL
Intervention: Face-to-face (FTF) pain management education in seven weekly sessions
Number of subjects: 90
Study 35709207 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 90
Study 32139267 — intervention group
Group type: EXPERIMENTAL
Intervention: Eldecalcitol (0.75 μg/day)
Number of subjects: 226
Study 32139267 — intervention group
Group type: COMPARATOR
Intervention: Control (no eldecalcitol)
Number of subjects: 226
Study 34228132 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 33396567 — intervention group
Group type: EXPERIMENTAL
Intervention: Long chain omega-3 polyunsaturated fatty acids (LC n-3 PUFAs) at a dosage of 1.8 g/day for 12 weeks
Number of subjects: 0
Study 33396567 — intervention group
Group type: COMPARATOR
Intervention: Placebo capsules
Number of subjects: 0
Study 35314131 — intervention group
Group type: EXPERIMENTAL
Intervention: Shared Decision Making (SDM) intervention
Number of subjects: 72
Study 35314131 — intervention group
Group type: COMPARATOR
Intervention: Control Preferences Scale (CPS)
Number of subjects: 72
Study 35314131 — intervention group
Group type: EXPERIMENTAL
Intervention: OPTION5
Number of subjects: 72
Study 33117349 — intervention group
Group type: EXPERIMENTAL
Intervention: High throughput screening platform using one-bead-one-compound (OBOC) libraries for IgE epitope detection.
Number of subjects: 0
Study 34378861 — intervention group
Group type: EXPERIMENTAL
Intervention: MYL‐1601D
Number of subjects: 71
Study 33225949 — intervention group
Group type: EXPERIMENTAL
Intervention: Sexual recombination
Number of subjects: 0
Study 33225949 — intervention group
Group type: COMPARATOR
Intervention: Asexual reproduction
Number of subjects: 0
Study 616512450 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitagliptin
Number of subjects: 0
Study 35995130 — intervention group
Group type: EXPERIMENTAL
Intervention: School-supervised asthma therapy
Number of subjects: 26
Study 35995130 — intervention group
Group type: COMPARATOR
Intervention: Enhanced usual care (receipt of an educational asthma workbook)
Number of subjects: 26
Study 34171959 — intervention group
Group type: EXPERIMENTAL
Intervention: Vericiguat (target dose 10 mg once daily)
Number of subjects: 5050
Study 34171959 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5050
Study 32375595 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness training focusing on present-moment attention and awareness
Number of subjects: 300
Study 32375595 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness (non-judgmental acceptance facet)
Number of subjects: 300
Study 32375595 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness
Number of subjects: 300
Study 34999610 — intervention group
Group type: EXPERIMENTAL
Intervention: Ulinastatin (300,000 units mixed with 100 mL of normal saline)
Number of subjects: 0
Study 34999610 — intervention group
Group type: COMPARATOR
Intervention: Control (100 mL of normal saline)
Number of subjects: 0
Study 33634589 — intervention group
Group type: EXPERIMENTAL
Intervention: liraglutide (0.6, 1.2, and 1.8 mg/day)
Number of subjects: 134
Study 33634589 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 134
Study 32791720 — intervention group
Group type: EXPERIMENTAL
Intervention: Ear molding treatment for 2 weeks within 3 days after birth
Number of subjects: 190
Study 32791720 — intervention group
Group type: COMPARATOR
Intervention: Usual care (waiting list)
Number of subjects: 190
Study 32791720 — intervention group
Group type: COMPARATOR
Intervention: Ear molding at 6th week if spontaneous recovery does not occur
Number of subjects: 190
Study 32791720 — intervention group
Group type: EXPERIMENTAL
Intervention: Physician and parent assessment of improvement, parent's anxiety, depression, and quality of life
Number of subjects: 190
Study 36512912 — intervention group
Group type: EXPERIMENTAL
Intervention: Durvalumab 1500 mg (Arm 1)
Number of subjects: 82
Study 36512912 — intervention group
Group type: EXPERIMENTAL
Intervention: Durvalumab 1500 mg plus tremelimumab 75 mg every 4 weeks (Arm 2)
Number of subjects: 82
Study 33323579 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic contact lens (TCL)
Number of subjects: 40
Study 33323579 — intervention group
Group type: COMPARATOR
Intervention: Control (no TCL)
Number of subjects: 40
Study 32962591 — intervention group
Group type: EXPERIMENTAL
Intervention: Mini-midvastus (MMV) approach
Number of subjects: 54
Study 32962591 — intervention group
Group type: COMPARATOR
Intervention: Medial parapatellar (MPP) approach
Number of subjects: 54
Study 35397540 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab
Number of subjects: 45
Study 35397540 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study 34404690 — intervention group
Group type: EXPERIMENTAL
Intervention: Pressure controlled continuous mandatory ventilation (PC-CMV)
Number of subjects: 27
Study 34404690 — intervention group
Group type: COMPARATOR
Intervention: Volume controlled continuous mandatory ventilation (VC-CMV)
Number of subjects: 27
Study 32619648 — intervention group
Group type: EXPERIMENTAL
Intervention: Omission of week 5 chemotherapy
Number of subjects: 940
Study 32619648 — intervention group
Group type: EXPERIMENTAL
Intervention: Dose reductions/delays of week 5 chemotherapy
Number of subjects: 940
Study 32619648 — intervention group
Group type: EXPERIMENTAL
Intervention: Receiving the target radiotherapy dose in >42 days
Number of subjects: 940
Study 33296320 — intervention group
Group type: EXPERIMENTAL
Intervention: Stochastic dominant learning swarm optimizer
Number of subjects: 0
Study 32858196 — intervention group
Group type: EXPERIMENTAL
Intervention: SI-locking screws (superoinferior)
Number of subjects: 20
Study 32858196 — intervention group
Group type: EXPERIMENTAL
Intervention: AP-locking screws (anteroposterior)
Number of subjects: 20
Study 32858196 — intervention group
Group type: EXPERIMENTAL
Intervention: Divergent screw orientation
Number of subjects: 20
Study 32858196 — intervention group
Group type: EXPERIMENTAL
Intervention: Parallel screw orientation
Number of subjects: 20
Study 35040196 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive treatment (INT)
Number of subjects: 568
Study 35040196 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional treatment (CONV)
Number of subjects: 568
Study 35040196 — intervention group
Group type: COMPARATOR
Intervention: Control population without diabetes
Number of subjects: 568
Study 33078318 — intervention group
Group type: COMPARATOR
Intervention: Flap fixation using sutures (FFS)
Number of subjects: 339
Study 33078318 — intervention group
Group type: COMPARATOR
Intervention: Flap fixation using tissue glue (FFG)
Number of subjects: 339
Study 33078318 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional wound closure (CON)
Number of subjects: 339
Study 32986075 — intervention group
Group type: EXPERIMENTAL
Intervention: Computerized virtual advisor program (virtual)
Number of subjects: 245
Study 32986075 — intervention group
Group type: COMPARATOR
Intervention: Previously validated peer advisor program (human)
Number of subjects: 245
Study 35650311 — intervention group
Group type: EXPERIMENTAL
Intervention: ENDOSWIR near-infrared optical imaging device
Number of subjects: 0
Study 35650311 — intervention group
Group type: COMPARATOR
Intervention: Control group (not exposed to SWIR light)
Number of subjects: 0
Study 34847302 — intervention group
Group type: EXPERIMENTAL
Intervention: RelyX Ultimate cement under normal atmospheric pressure
Number of subjects: 40
Study 34847302 — intervention group
Group type: EXPERIMENTAL
Intervention: RelyX Unicem cement under normal atmospheric pressure
Number of subjects: 40
Study 34847302 — intervention group
Group type: EXPERIMENTAL
Intervention: RelyX Ultimate cement under hyperbaric pressure
Number of subjects: 40
Study 34847302 — intervention group
Group type: EXPERIMENTAL
Intervention: RelyX Unicem cement under hyperbaric pressure
Number of subjects: 40
Study 34076569 — intervention group
Group type: EXPERIMENTAL
Intervention: Tai Chi group (TCG)
Number of subjects: 65
Study 32072743 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV combination prevention package including universal testing and treatment
Number of subjects: 48000
Study 32072743 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV testing with streamlined, algorithmic approach
Number of subjects: 48000
Study 35086944 — intervention group
Group type: EXPERIMENTAL
Intervention: High amount/moderate intensity exercise (16 kcal/kg/week at 50% V̇O2 reserve)
Number of subjects: 162
Study 35086944 — intervention group
Group type: EXPERIMENTAL
Intervention: High/vigorous exercise (16 kcal/kg/week at 75% V̇O2 reserve)
Number of subjects: 162
Study 35086944 — intervention group
Group type: EXPERIMENTAL
Intervention: Low/moderate exercise (10 kcal/kg/week at 50% V̇O2 reserve)
Number of subjects: 162
Study 35086944 — intervention group
Group type: EXPERIMENTAL
Intervention: Low/moderate plus diet (10 kcal/kg/week at 50% V̇O2 reserve plus calorically restricted diet)
Number of subjects: 162
Study 35368954 — intervention group
Group type: EXPERIMENTAL
Intervention: Nimodipine combined with magnesium sulfate
Number of subjects: 96
Study 35368954 — intervention group
Group type: COMPARATOR
Intervention: Magnesium sulfate (single drug group)
Number of subjects: 96
Study 32436287 — intervention group
Group type: EXPERIMENTAL
Intervention: TCA 35%
Number of subjects: 20
Study 32436287 — intervention group
Group type: COMPARATOR
Intervention: Phenol 88%
Number of subjects: 20
Study 35758171 — intervention group
Group type: EXPERIMENTAL
Intervention: Social determinants of health domains (economic stability, health care, education, neighborhood and built environment, social and community context)
Number of subjects: 2505
Study 35758171 — intervention group
Group type: EXPERIMENTAL
Intervention: Access to Healthcare
Number of subjects: 2505
Study 33004239 — intervention group
Group type: EXPERIMENTAL
Intervention: DAR-901 vaccine (1 mg, three intradermal injections at 0, 2, and 4 months)
Number of subjects: 667
Study 33004239 — intervention group
Group type: COMPARATOR
Intervention: Saline placebo (three intradermal injections at 0, 2, and 4 months)
Number of subjects: 667
Study 33004239 — intervention group
Group type: EXPERIMENTAL
Intervention: DAR-901 vaccine (1 mg)
Number of subjects: 667
Study 32893741 — intervention group
Group type: EXPERIMENTAL
Intervention: WATER
Number of subjects: 12
Study 32893741 — intervention group
Group type: EXPERIMENTAL
Intervention: CARBON
Number of subjects: 12
Study 32893741 — intervention group
Group type: COMPARATOR
Intervention: CONTROL
Number of subjects: 12
Study 34980634 — intervention group
Group type: EXPERIMENTAL
Intervention: Regional Repolarisation Instability Index (R2I2)
Number of subjects: 440
Study 34980634 — intervention group
Group type: EXPERIMENTAL
Intervention: Peak Electrical Restitution Slope
Number of subjects: 440
Study 33257778 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized nutritional counseling in the first 3 months post HSCT
Number of subjects: 46
Study 33257778 — intervention group
Group type: COMPARATOR
Intervention: General qualitative education without reinforcement (Control Group)
Number of subjects: 46
Study 35750727 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital surgical guide (CAD/CAM)
Number of subjects: 42
Study 35750727 — intervention group
Group type: COMPARATOR
Intervention: Traditional implant guide (traditional impression)
Number of subjects: 42
Study 35750727 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 42
Study 33759846 — intervention group
Group type: EXPERIMENTAL
Intervention: Online interactive case-based training on shared decision-making (SDM)
Number of subjects: 97
Study 33759846 — intervention group
Group type: COMPARATOR
Intervention: Online interactive case-based training on evidence-based practice (EBP) related to medication use in autism
Number of subjects: 97
Study 32756101 — intervention group
Group type: EXPERIMENTAL
Intervention: Movimente intervention program (teacher training, improvements in PA environment, educational strategies)
Number of subjects: 999
Study 32756101 — intervention group
Group type: COMPARATOR
Intervention: Control group (traditional schedule)
Number of subjects: 999
Study 35060851 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisolone (15 mg/m2 for 6 days)
Number of subjects: 271
Study 35060851 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 271
Study 35060851 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisolone
Number of subjects: 271
Study 34837824 — intervention group
Group type: EXPERIMENTAL
Intervention: ctDCS (cathodal transcranial direct current stimulation) at -1.0 mA for 20 minutes over 5 days
Number of subjects: 25
Study 32127304 — intervention group
Group type: EXPERIMENTAL
Intervention: CAD/CAM splints
Number of subjects: 30
Study 32127304 — intervention group
Group type: COMPARATOR
Intervention: Conventional splints
Number of subjects: 30
Study 35285944 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral low-dose isotretinoin (0.2–0.4 mg/kg/d) combined with 30% salicylic acid chemical peeling
Number of subjects: 33
Study 35285944 — intervention group
Group type: COMPARATOR
Intervention: Oral low-dose isotretinoin
Number of subjects: 33
Study 35285944 — intervention group
Group type: COMPARATOR
Intervention: 30% salicylic acid chemical peeling
Number of subjects: 33
Study 32692788 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral prednisolone
Number of subjects: 50
Study 32692788 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical budesonide irrigations
Number of subjects: 50
Study 32692788 — intervention group
Group type: COMPARATOR
Intervention: Oral doxycycline
Number of subjects: 50
Study 35008039 — intervention group
Group type: EXPERIMENTAL
Intervention: Knowledge of Results (KR)
Number of subjects: 29
Study 35008039 — intervention group
Group type: EXPERIMENTAL
Intervention: Athlete-driven KR
Number of subjects: 29
Study 35008039 — intervention group
Group type: EXPERIMENTAL
Intervention: KR
Number of subjects: 29
Study 35008039 — intervention group
Group type: COMPARATOR
Intervention: No Feedback (NoFb)
Number of subjects: 29
Study 32467145 — intervention group
Group type: EXPERIMENTAL
Intervention: Ph‐like cases
Number of subjects: 88
Study 32467145 — intervention group
Group type: EXPERIMENTAL
Intervention: Ph‐like profile
Number of subjects: 88
Study 32467145 — intervention group
Group type: EXPERIMENTAL
Intervention: Ph‐like patients
Number of subjects: 88
Study 32687588 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced-dose capecitabine plus cetuximab as maintenance therapy
Number of subjects: 47
Study 32687588 — intervention group
Group type: COMPARATOR
Intervention: Fluorouracil-based chemotherapy combined with cetuximab (induction therapy)
Number of subjects: 47
Study 32687588 — intervention group
Group type: COMPARATOR
Intervention: Induction therapy
Number of subjects: 47
Study 32687588 — intervention group
Group type: EXPERIMENTAL
Intervention: Maintenance therapy
Number of subjects: 47
Study 36348150 — intervention group
Group type: EXPERIMENTAL
Intervention: LED therapy (LEDT)
Number of subjects: 42
Study 36348150 — intervention group
Group type: COMPARATOR
Intervention: Control (CTRL)
Number of subjects: 42
Study 34579095 — intervention group
Group type: EXPERIMENTAL
Intervention: RES-500 (500 mg RES/day)
Number of subjects: 36
Study 34579095 — intervention group
Group type: EXPERIMENTAL
Intervention: RES-1000 (1000 mg RES/day)
Number of subjects: 36
Study 34579095 — intervention group
Group type: EXPERIMENTAL
Intervention: RES (both doses)
Number of subjects: 36
Study 34579095 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 35048107 — intervention group
Group type: EXPERIMENTAL
Intervention: Polypill (aspirin, atorvastatin, hydrochlorothiazide, valsartan)
Number of subjects: 2400
Study 35048107 — intervention group
Group type: COMPARATOR
Intervention: Control (no polypill)
Number of subjects: 2400
Study 35048107 — intervention group
Group type: EXPERIMENTAL
Intervention: Polypill (aspirin, atorvastatin, hydrochlorothiazide, valsartan) in participants with pNASH
Number of subjects: 2400
Study 35048107 — intervention group
Group type: COMPARATOR
Intervention: Control (no polypill) in participants without pNASH
Number of subjects: 2400
Study 35048107 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants with pNASH
Number of subjects: 2400
Study 32895043 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary education (4 sessions)
Number of subjects: 112
Study 36469332 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonmydriatic ultra-widefield (NM UWF) imaging on the day of a scheduled diabetes clinic visit
Number of subjects: 740
Study 36469332 — intervention group
Group type: COMPARATOR
Intervention: Usual screening (encouraged to arrange optometrist screening)
Number of subjects: 740
Study 32613229 — intervention group
Group type: EXPERIMENTAL
Intervention: iCanCope app (smartphone-based pain self-management program)
Number of subjects: 60
Study 32613229 — intervention group
Group type: COMPARATOR
Intervention: Symptom tracking only app (control)
Number of subjects: 60
Study 32340074 — intervention group
Group type: COMPARATOR
Intervention: Conventional with Prevention (C + P)
Number of subjects: 1144
Study 32340074 — intervention group
Group type: EXPERIMENTAL
Intervention: Biological with Prevention (B + P)
Number of subjects: 1144
Study 32340074 — intervention group
Group type: EXPERIMENTAL
Intervention: Prevention Alone (PA)
Number of subjects: 1144
Study 32340074 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatment arms (C + P, B + P, PA)
Number of subjects: 1144
Study 35623727 — intervention group
Group type: EXPERIMENTAL
Intervention: V block
Number of subjects: 140
Study 35623727 — intervention group
Group type: COMPARATOR
Intervention: H block
Number of subjects: 140
Study 33945339 — intervention group
Group type: COMPARATOR
Intervention: Hamstring tendon (HT) autograft alone
Number of subjects: 0
Study 33945339 — intervention group
Group type: EXPERIMENTAL
Intervention: Bone-patellar tendon-bone (BPTB) graft
Number of subjects: 0
Study 33945339 — intervention group
Group type: EXPERIMENTAL
Intervention: Hamstring tendon (HT) autograft with lateral extra-articular tenodesis (LET)
Number of subjects: 0